April 30, 2014 — Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a new ultrasound device that could help identify arterial plaque that is at high risk of breaking off and causing heart attack or stroke.

April 30, 2014 — Celladon Corp. announced its lead product candidate, Mydicar, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative. Celladon is a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies.

April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the final pivotal trial of tecarfarin. Tecarfarin is positioned to be the only oral anticoagulant therapy for patients with prosthetic heart valves (PHV) specifically identified in the label.

Healthcare imaging specialist Barco launched its MDSC-8258, a 58-inch surgical display designed for 4K imaging in hybrid operating rooms and interventional suites. 

John Muir Health announced that its Concord, Calif., medical center is one of the first hospitals in Northern California to implant a miniature cardiac monitor in a patient – the Reveal Linq Insertable Cardiac Monitor (ICM) System.

 When an unmanned supply mission launched into space on April 18, bound for the International Space Station, it meant something extraordinary to Peter Lee, a cardiothoracic surgeon at The Ohio State University Wexner Medical Center. That is because his research experiment is on board.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now